Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Edupuganti S, et al. Among authors: gamble t. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. Lancet HIV. 2025. PMID: 39667379 Clinical Trial.
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, Chege W, Yacovone M, Hanscom B, Heptinstall J, Seaton KE, Zhang L, Miner MD, Eaton A, Weiner JA, Mayer K, Kalams S, Stephenson K, Julg B, Caskey M, Nussenzweig M, Gama L, Barouch DH, Ackerman ME, Tomaras GD, Huang Y, Montefiori D; HVTN 130/HPTN 089 Study Team. Sobieszczyk ME, et al. Among authors: gamble t. Lancet HIV. 2023 Oct;10(10):e653-e662. doi: 10.1016/S2352-3018(23)00140-6. Lancet HIV. 2023. PMID: 37802566 Free PMC article. Clinical Trial.
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, Cohen MS; HPTN 052-ACTG Study Team. Grinsztejn B, et al. Among authors: gamble t. Lancet Infect Dis. 2014 Apr;14(4):281-90. doi: 10.1016/S1473-3099(13)70692-3. Epub 2014 Mar 4. Lancet Infect Dis. 2014. PMID: 24602844 Free PMC article. Clinical Trial.
Virologic outcomes in early antiretroviral treatment: HPTN 052.
Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen YQ, Cohen MS, Fogel JM. Eshleman SH, et al. Among authors: gamble t. HIV Clin Trials. 2017 May;18(3):100-109. doi: 10.1080/15284336.2017.1311056. Epub 2017 Apr 7. HIV Clin Trials. 2017. PMID: 28385131 Free PMC article. Clinical Trial.
HIV Prevention Trials Network 078: High Prevalence of Hepatitis C Virus Antibodies Among Urban US Men Who Have Sex With Men, Independent of Human Immunodeficiency Virus Status.
Irvin R, Gamble T, Malone J, Wang Z, Wilson E, Hughes JP, Farley J, Mayer KH, Del Rio C, Batey DS, Cummings V, Remien RH, Beyrer C, Thio CL. Irvin R, et al. Among authors: gamble t. Clin Infect Dis. 2021 Oct 5;73(7):e2205-e2210. doi: 10.1093/cid/ciaa1869. Clin Infect Dis. 2021. PMID: 33346798 Free PMC article.
Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load.
Fogel JM, Bonsall D, Cummings V, Bowden R, Golubchik T, de Cesare M, Wilson EA, Gamble T, Del Rio C, Batey DS, Mayer KH, Farley JE, Hughes JP, Remien RH, Beyrer C, Fraser C, Eshleman SH. Fogel JM, et al. Among authors: gamble t. J Antimicrob Chemother. 2020 Dec 1;75(12):3510-3516. doi: 10.1093/jac/dkaa352. J Antimicrob Chemother. 2020. PMID: 32772080 Free PMC article.
HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States.
Remien RH, Dacus JD, Farley JE, Hughes JP, Gamble T, Wang ZZ, Batey DS, Mayer KH, Del Rio C, Balán IC, Irvin R, Mitchell KM, Cummings V, Eshleman SH, Conserve DF, Knox J, Yu K, Beyrer C; HPTN 078 Study Team. Remien RH, et al. Among authors: gamble t. AIDS. 2023 Feb 1;37(2):217-231. doi: 10.1097/QAD.0000000000003411. Epub 2022 Oct 21. AIDS. 2023. PMID: 36541636 Free PMC article. Clinical Trial.
Comparing recruitment strategies to engage hard-to-reach men who have sex with men living with HIV with unsuppressed viral loads in four US cities: Results from HPTN 078.
Beyrer C, Malone J, Baral S, Wang Z, Rio CD, Mayer KH, Batey DS, Farley J, Gamble T, Stanton J, Hughes JP, Wilson E, Irvin R, Guevara-Perez O, Bocek A, Bruce J, Gaston R, Cummings V, Remien RH; HPTN 078 Study Team. Beyrer C, et al. Among authors: gamble t. J Int AIDS Soc. 2021 Sep;24(9):e25798. doi: 10.1002/jia2.25798. J Int AIDS Soc. 2021. PMID: 34473400 Free PMC article.
180 results